MedWatch

Viagra to get a run for its money

The Danish market is about to be flooded with cheap versions of Viagra, as 15 companies are already poised to launch generic versions of the anti-impotence drug.

Foto: Colourbox

A number of companies are ready to make money off of Danish men in need of medicinal help in the bedroom. Pfizer’s Danish patent on the anti-impotence drug Viagra, containing the active substance sildenafil citrate, will expire on July 24 following 15 years of market exclusivity, and so far 15 companies have had marketing approvals for generic versions approved by the Danish medicines authorities.

The only Danish company to venture into this area is the parallel importer and generics manufacturer, Orifram. Orifarm has experience with selling generic versions of Viagra on the Finnish market where the drug has already lost patent. Aside from the single Danish company, it is major international generics giants, such as Teva, Actavis, Mylan and Novartis’ generics subsidiary, Sandoz, which are looking to enter the market.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier